1/23
05:09 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Werewolf Therapeutics (NASDAQ:HOWL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
04:46 am
howl
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]
12/23
07:06 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.
High
Report
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.
12/19
11:05 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
Low
Report
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.
12/19
10:00 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.
Medium
Report
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.
12/19
07:19 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/18
08:00 am
howl
Werewolf Therapeutics Announces Pipeline and Business Updates
High
Report
Werewolf Therapeutics Announces Pipeline and Business Updates
11/25
07:31 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/18
01:13 pm
howl
Werewolf Therapeutics (NASDAQ:HOWL) had its price target lowered by analysts at Bank of America Corporation from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Werewolf Therapeutics (NASDAQ:HOWL) had its price target lowered by analysts at Bank of America Corporation from $8.00 to $7.00. They now have a "buy" rating on the stock.